Moving away (finally) from doublet therapy in lung cancer: immunotherapy and KEYNOTE-189

Treatment of patients with advanced non-small cell lung cancer (NSCLC) has undergone dramatic changes in the recent decade. We have now established a treatment model based on precision medicine: detection of driver mutations and utilization of targeted agents as well as determination of programmed death-ligand 1 (PD-L1) status and integration of immunotherapy.